One in three women taking long-term hormonal (endocrine) therapy for invasive breast cancer stop their treatment before the end of the recommended five-year period, according to a major follow-up study, which reveals that women looked after in specialised oncology units are more likely to continue therapy than those cared for by family doctors.
More...